Joint involvement in inflammatory bowel disease: Managing inflammation outside the digestive system

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 1, 2010, Pages 81-89

  De Vos, Martine ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Ankylosing spondylitis; Arthritis; Genetics; HIF; Hypoxia inducible factor; Inflammatory bowel diseases; Placental growth factor; PlGF; Sacroiliitis; Th17; TNF

Indexed keywords

ADALIMUMAB; ALPHA4BETA7 INTEGRIN; AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; ETORICOXIB; HLA B27 ANTIGEN; HYPOXIA INDUCIBLE FACTOR; INFLIXIMAB; JANUS KINASE 2; LYMPHOCYTE ANTIGEN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTHROPATHY; BACKACHE; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INCIDENCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHENOTYPE; PROTEIN DOMAIN; REVIEW; SACROILIITIS; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SPONDYLITIS; TH17 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; RATS;

EID: 77951681327     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.75     Document Type: Review

References (70)

1. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in infammatory bowel disease: their articular distribution and natural history. Gut 42, 387-1381 (1998).
2. Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin. Rheumatol. 19, 51-57 (2000).
3. Rudwaleit M, van der Heijde D, Landewé R et al. The development of Assessment of SpondyloArthritis International Society classifcation criteria for axial spondyloarthritis (part II): validation and fnal selection. Ann. Rheum. Dis. 68, 777-783 (2009).
4. Palm O, Bernklev T, Moum B, Gran JT. Non-infammatory joint pain in patients with infammatory bowel disease is prevalent and has a signifcant impact on health related quality of life. J. Rheumatol. 32, 1755-1759 (2005).
5. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 96, 339-344 (1989).
6. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut infammation in patients with spondylarthropathy. Gastroenterology 110, 1696-1703 (1996).
7. Demetter P, Van Huysse JA, De Keyser F et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J. Pathol. 198, 517-522 (2002).
8. D'Inca R, Podswiadek M, Ferronato A et al. Articular manifestations in infammatory bowel disease patients: a prospective study. Dig. Liver Dis. 41, 565-569 (2009).
9. De Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in infammatory bowel disease: prevalence and HLA association. J. Rheumatol. 27, 2860-2865 (2000).
10. Peeters H, Vander Cruyssen B, Mielants H et al. Clinical and genetic factors associated with sacroilliitis in Crohn's disease. J. Gastroenterol. Hepatol. 23, 132-137 (2008).
11. Scott WW Jr, Fishman EK, Kuhlman JE et al. Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/clinical correlation. Skeletal Radiol. 19, 207-210 (1990).
12. McEniff N, Eustace S, McCarthy C et al. Asymptomatic sacroiliitis in infammatory bowel disease. Assessment by computed tomography. Clin. Imaging 19, 258-262 (1995).
13. Salvarani C, Fries W Clinical futures and epidemiology of spondyloarthritides associated with infammatory bowel disease. World J. Gastroenterol. 15, 2449-2455 (2009).
14. van der Linden SM, Valkenburgh HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLAB27 positive individuals. A comparison of relatives of spondylitis patients with general population. Arthr. Rheum. 27, 241-249 (1984).
15. Saraux A, Guillemin F, Guggenpuhl P et al. Prevalence of spondyloarthropathy in France: 2001. Ann. Rheum. Dis. 64, 1431-1435 (2005).
16. Braun J, Bollow M, Remlinger G et al Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 41, 58-67 (1998).
17. Baeten D, De Keyser F. The histopathology of spondyloarthropathy (review). Curr. Mol. Med. 4, 1-12 (2004).
18. 7 integrins in infamed synovial tissue from patients with early spondyloarthropathy compared to rheumatoid arthritis. J. Rheumatol. 25, 1932-1937 (1998).
19. Baeten D, Demetter P, Cuvelier CA et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial infammation in spondyloarthropathy. J. Pathol. 196, 343-350 (2002).
20. Demetter P, De Vos M, Van Huysse JA et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann. Rheum. Dis. 64, 321-324 (2005).
21. Jacques P, Mielants H, Coppieters K, De Vos M, Elewaut D. The intimate relationship between gut and joint in spondyloarthropathies (review). Curr. Opin. Rheumatol. 19, 353-357 (2007).
22. Hindryckx P, Serry G, Laukens D, Peeters H, De Vos M. Increased intestinal VEGF expression and mucosal vascularization in patients with spondylarthropathy. Gastroenterology 136, A-559 (2009).
23. Polzer K, Baeten D, Soleiman A et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritis joints. Ann. Rheum. Dis. 67, 1610-1616 (2008).
24. Schett G. Joint remodelling in infammatory diseases. Ann. Rheum. Dis. 66(Suppl. 3), iii42-iii44 (2007).
25. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
26. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic infammatory joint and intestinal diseases. J. Exp. Med. 205, 331-337 (2008).
27. Kontoyiannis D, Boulougouris G, Manoloukos M et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like infammatory bowel disease. J. Exp. Med. 196, 1563-1574 (2002).
28. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to infammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J. Immunol. 150, 4168-4178 (1993).
29. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA B27 transgene rats selectively colonized with Bacteroides vulgatus and Eschericia coli. Infect. Immunol. 67, 2969-2974 (1999).
30. Rath HC, Schultz M, Freitag R et al Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69, 2277-2285 (2001).
31. + T Cells: Selective Impairment of Costimulatory Molecules Engagement by Mature HLA-B27 Arthritis Rheum. 56, 1478-1489 (2007).
32. 2-microglobulin-transgenic Rat Lines. Arthritis Rheum. 58, 3425-3429 (2008).
33. Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA HLA-B27 Up-regulation Causes Accumulation of Misfolded Heavy Chains and Correlates with the Magnitude of the Unfolded Protein Response in Transgenic Rats: Implications for the Pathogenesis of Spondylarthritis-like Disease. Arthritis Rheum. 56, 215-223 (2007).
34. 2-microglobulin Curbs HLA-B27 Misfolding and Promotes Arthritis and Spondylitis Without Colitis in Male HLA-B27-transgenic Rats. Arthritis Rheum. 54, 1317-1327 (2006).
35. Reveille JD. Recent studies on the genetic basis of ankylosing spondylitis (review). Curr. Rheumatol. Rep. 11, 340-348 (2009).
36. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defnes more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 29, 175 (2008).
37. Manel N, Unutmaz D, Littman DR. The differentiation of human Th17 cells require transforming growth factor-b and induction of the nuclear receptor RORg. Nat. Immunol. 9, 641-649 (2008).
38. Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-b are required for differentiation of human Th17 cells. Nature 454, 350-352 (2008).
39. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167 (2009).
40. Schmechel S, Konrad A, Diegelman J et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Infamm. Bowel Dis. 14, 204-212 (2008).
41. Ciccia F, Bombardieri M, Principato A et al Overexpression of interleukin-23, but Not interleukin-17, As An Immunologic Signature of Subclinical Intestinal Infammation in Ankylosing Spondylitis. Arthritis Rheum. 60, 955-965 (2009).
42. Melis L, Vandooren B, Kruithof E et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.107649 (2009) (Epub ahead of print).
43. Laukens D, Peeters H, Marichal D et al. CARD15 gene polymorphisms in patients with spondyloarthorpathies identify a specifc phenotype previously related to Crohn's disease. Ann. Rheum. Dis. 64, 930-935 (2005).
44. Micelli-Richard C, Zouali H, Lesage S et al CARD15/NOD2 Analyses in Spondyloarthropathy. Arthritis Rheum. 46, 1405-1406 (2002).
45. Craene AM, Bradbury L, Van Heel DA et al Role of NOD2 Variants in Spondyloarthritis. Arthritis Rheum. 46, 1629-1633 (2002).
46. Laukens D, Peeters H, Cruyssen BV et al. Altered gut transcriptome in spondyloarthropathy. Ann. Rheum. Dis. 65, 1293-1300 (2006).
47. Georges M, Laukens D, Libioulle C et al. Evidence for signifcant overlap between common risk variants for Crohn's disease and ankylosing spondylitis. Acta Gastroenterol. Belg. 72, 103 (2009).
48. Forrest K, Symmons D, Foster P Systematic Review: Is Ingestion of Paracetamol or Non-steroidal Antiinfammatory Drugs Associated with Exacerbations of Infammatory Bowel Disease? Aliment Pharmacol. Ther. 20, 1035-1043 (2004).
49. Feagins LA, Cryer BL. Do non-steroidal anti-infammatory drugs cause exacerbations of infammatory bowel disease? Dig. Dis. Sci. 55(2), 226-232 (2009).
50. Kefalakes H, Stylianedes TJ, Amanakis G, Kolios G. Exacerbation of infammatory bowel disease associated with the use of nonsteroidal antiinfammatory drugs: myth or reality? Eur. J. Clin. Pharmacol. 65, 963-970 (2009).
51. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections or stress trigger fares in IBD? Am. J. Gastroenterol. 104, 1298-1313 (2009).
52. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis A P, Gleim G. Effects of nonsteroidal antiinfammatory drugs on infammatory bowel disease: a case-control study. Am. J. Gastroenterol. 95, 1949-1954 (2000).
53. Takeuchi K, Smale S, Premchand P et al. Prevalence and mechanism of non-steroidal antiinfammatory drug induced clinical relapse in patients with IBD. Clin. Gastroenterol. Hepatol. 4, 196-202 (2006).
54. Bonner GF, Fakhri A, Vennamanen SR. A long-term cohort study of non-steroidal antiinfammatory drug use and disease activity in outpatients with infammatory bowel diseases. Infamm. Bowel Dis. 10, 751-757 (2004).
55. Sandborn WJ, Stenson WF, Brynskov J et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomised placebo controlled pilot study. Clin. Gastroenterol. Hepatol. 4, 203-211 (2006).
56. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective COX-2 inhibitor in infammatory bowel diseases. Am. J. Gastroenterol. 101, 311-317 (2006).
57. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann. Rheum. Dis. 65, 423-432 (2006).
58. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-a blockade with infiximab on articular symptoms. Lancet 356, 1821-1822 (2000).
59. Generini S, Giacomelli R, Fedi R et al. Infiximab in spondyloarthropathy associated with Crohn's disease: an open study on the effcacy of inducing and maintaining remission at musculoskeletal and gut manifestations. Ann. Rheum. Dis. 63, 1664-1669 (2004).
60. Braun J, Baraliakos X, Listing J et al Differences in the Incidence of Fares or New Onset of Infammatory Bowel Disease in Patients with Ankylosing Spondylitis Exposed to Therapy with Anti-TNF Agents. Arthritis Rheum. 57, 639-647 (2007).
61. Hindryckx P, Waeytens A, Laukens D, Peeters H, Van Huysse J, De Vos M. Absence of placental growth factor aggravates DSS-induced acute colonic injury. J. Crohns Colitis 3(1), S124-S125 (2009).
62. Hindryckx P, Laukens D, Jacques P, Peeters H, Vandenabeele P, De Vos M. Protective effect of prolyl hydroxylase inhibition on tumor necrosis factor-induced intestinal pathology. Presented at: GASTRO 2009 UEGW/WCOG. London, UK, 21-25 November 2009.
63. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin 12 antibody for active Crohns disease. N. Engl. J. Med. 351, 2069-2079 (2004).
64. Burakoff R, Barish CF, Riff D et al. A Phase 1/2 trial of STA 5326, an oral interleukin 12/23 inhibitor in patients with active moderate to severe Crohn's disease. Infamm. Bowel Dis. 12, 558-565 (2006).
65. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373, 633-640 (2009).
66. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohns disease. Am. J. Gastroenterol. 104, 2768-2773 (2009).
67. Canete JD, Celis R, Hernandez MV, Pablos JL, Sanmarti R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.113233 (2009).
68. Kaser A, Lee AH, Franke A et al. XBP1 links ER stress to intestinal infammation and confers genetic risk for human infammatory bowel disease. Cell 134, 743-756 (2008).
69. Kaser A, Blumberg RS. Endoplasmic reticulum stress in the intestinal epithelium and infammatory bowel disease. Semin. Immunol. 21, 156-163 (2009).
70. Todd DJ, Lee AH, Glimcher LA et al. The endoplasmatic reticulum stress response in immunity and autoimmunity (review). Nat. Rev. 8, 663-674 (2008).